Truly 200 LDP is the 1st FDA cleared glove with low dermatitis potential and chemotherapy drug tested claim in the dental industry. The gloves are specifically engineered as accelerator-free with innovative manufacturing approach to reduce the potential of Type I & Type IV allergic reactions. Truly 200 LDP formulation offers maximum stress-free comfort and greater tensile strength to prevent tearing.

    • 2.8 - 4.7 mils thickness

    • Fingertip Textured

    • Ambidextrous

    • Nitrile

    • Non-Sterile

    • Light Blue color

  • 3210 Series
    200 pieces per box by weight
    10 boxes per case

    Available in sizes XS-XL
    CR3215 (X-Small)
    CR3216 (Small)
    CR3217 (Medium)
    CR3218 (Large)
    CR3219 (X-Large)

    • Meets and Exceeds ASTM D6319 Standard

    • Tensile Strength Before Aging: 28-32 MPa; After Aging: 29-33 MPa

    • Ultimate Elongation Before Aging: 520-560%; After Aging: 520-560%

    • Acceptable Quality Level (AQL): 1.5

Key Features and Benefits

  • FDA cleared low dermatitis claim greatly reduces incidence of contact dermatitis

  • Accelerator-Free nitrile reduces Type I & Type IV allergic reactions

  • Chemotherapy drug permeation tested for resistance to penetration by select drugs

  • Exclusive SmartGrip® technology deliver optimal wet grip performance

PROTECTION AGAINST FENTANYL

Tested and certified as the first nitrile gloves with resistance against Fentanyl (510k granted by FDA).

CHEMOTHERAPY DRUG TESTED

Chemotherapy drug permeation tested for resistance to penetration by select drugs

PATENDED LOW DERMA TECHNOLOGY

Patented Low Derma Technology eliminates the chemical accelerators commonly found in nitrile, reducing the risk of Type I & Type IV hypersensitivities.

ASTM D6978 Chemotherapy Drugs Permeation Test *denotes mandatory chemotherapy drugs

Chemotherapy Drugs and Concentration Concentration Minimum Breakthrough Detection Time in Minutes
Carmustine* (BCNU) 3.3 mg/ml Do Not Use
Cisplatin 1.0 mg/ml > 240 min
Cyclophosphamide (Cytoxan)* 20.0 mg/ml > 240 min
Cytarabine 100 mg/ml > 240 min
Dacarbazine (DTIC) 10.0 mg/ml > 240 min
Doxorubicin Hydrochloride* 2.0 mg/ml > 240 min
Etoposide* 20.0 mg/ml > 240 min
Fluorouracil* 50.0 mg/ml > 240 min
Ifosfamide 50.0 mg/ml > 240 min
Methotrexate 25.0 mg/ml > 240 min
Mitomycin C 0.5 mg/ml > 240 min
Mitoxantrone 2.0 mg/ml > 240 min
Paclitaxel (Taxol)* 6.0 mg/ml > 240 min
Thiotepa* 10.0 mg/ml Do Not Use
Vincristine Sulfate 1.0 mg/ml > 240 min
Chemotherapy Drugs and Concentration Concentration Minimum Breakthrough Detection Time in Minutes
Fentanyl Citrate Injection 100mcg/2ml > 240 min

Awards

FAQ

  • Contact dermatitis is a skin condition that develops from repeated exposure to certain chemicals. In dental, this exposure is commonly found from remnants of chemical accelerators used in the manufacture of gloves.

  • D Chemical accelerators are used in glove manufacturing to stabilize synthetic rubber molecules into strong and durable gloves. These accelerators are the major cause of Allergic Contact Dermatitis reactions.

  • Accelerator-Free gloves are manufactured without the use of accelerator chemicals such as Mercaptobenzothiazole (MBTs), thiazoles, thiurams and dithiocarbamates to help protect glove users from a nonallergic reaction to any of the numerous irritants from both glove and non-glove associated sources.

  • For nitrile glove users, the possibility of glove allergy should be considered in all case of hand dermatitis. the usual culprits are additive chemicals called accelerators. because of their effects on the chemical reactions that change liquid rubber formulations into tough rubber films. Accelerator-free nitrile gloves are strongly recommended for people who are sensitive to these additives.

  • It varies, depends on the skin conditions (personal experience). The effectiveness can lead from 1 week to several months.